What we do Everest Organics Ltd manufactures Active Pharmaceutical Ingredients and intermediates, focusing on bulk drugs including ciprofloxacin, omeprazole, and enrofloxacin. |
Founded in 1,993 |
Market share A notable player in India's pharmaceutical ingredient sector with expanded manufacturing capacities. |
Problem solved Addresses the need for high-quality active pharmaceutical ingredients for generic and branded drug manufacturers. |
Top clients or who we serve Serves pharmaceutical companies domestically and internationally, mainly B2B customers in bulk drug supply. |
Key management Dr. Sri Kakarlapudi Sirisha (Managing Director & CEO), Mr. Srikakarlapudi Harikrishna (Whole-Time Director), Mr. Ramakrishna Peruri (CFO). |
Our journey and innovations Incorporated in 1993, expanded capacity multiple times including ciprofloxacin and esomeprazole; continuous product and capacity expansion till 2025. |
Where we operate Operations primarily in India with a strong export segment contributing to revenues. |
Top products or what we offer Active Pharmaceutical Ingredients like Ciprofloxacin, Omeprazole, Enrofloxacin, Benzimidazole, and Esomeprazole Magnesium. |
Top brands - |
Raw materials needed Chemical precursors and intermediates required for bulk drug manufacturing. |
Raw materials supplier - |
Recurring vs cyclical contribution Revenue is largely recurring from consistent bulk drug orders with some cyclical variations due to regulatory approvals and demand. |
Our industry position Well established in domestic and export pharmaceutical ingredient markets with increasing capacity and product portfolio. |
Financial highlights FY 2024-25 revenue Rs 160.17 crore, net loss Rs 1.29 crore reflecting near breakeven; invested in capacity expansions. |
Geographical revenue split Domestic segment 83%, export segment 17% revenue contribution as of FY 2024-25. |
Order book - |
Whats driving growth Capacity expansion, increasing demand for generic APIs, new product additions, and growing export markets. |
Our future plans Further capacity increase, new product pipeline expansion, and regulatory approvals to fuel growth. |
Our green promise - |
Our people and values Committed workforce fostering ethical standards and compliance, with focus on sustainable growth. |
Key challenges ahead Regulatory approvals, environmental clearances, market competition, and raw material price volatility. |
Interesting facts Successfully increased production capacity multiple times and added new products like esomeprazole magnesium over 30 years. |
Risks and strategy Risk from regulatory delays and competition; mitigation includes product diversification and compliance adherence. |
